KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biogen (BIIB) Gross Margin (2016 - 2025)

Biogen (BIIB) has 17 years of Gross Margin data on record, last reported at 78.26% in Q4 2025.

  • For Q4 2025, Gross Margin rose 203.0% year-over-year to 78.26%; the TTM value through Dec 2025 reached 75.69%, down 43.0%, while the annual FY2025 figure was 75.69%, 43.0% down from the prior year.
  • Gross Margin reached 78.26% in Q4 2025 per BIIB's latest filing, up from 73.39% in the prior quarter.
  • Across five years, Gross Margin topped out at 89.14% in Q1 2022 and bottomed at 62.81% in Q2 2022.
  • Average Gross Margin over 5 years is 77.13%, with a median of 76.73% recorded in 2024.
  • The widest YoY moves for Gross Margin: up 689bps in 2022, down -2062bps in 2022.
  • A 5-year view of Gross Margin shows it stood at 75.85% in 2021, then rose by 2bps to 77.56% in 2022, then decreased by -5bps to 73.93% in 2023, then grew by 3bps to 76.23% in 2024, then increased by 3bps to 78.26% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 78.26% in Q4 2025, 73.39% in Q3 2025, and 77.13% in Q2 2025.